Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 144/A

PTC Therapeutics, Inc.

PTCTNASDAQEQUITYCurrent

SEC Filing

Filed Aug 25, 2026Accepted Aug 25, 2026, 4:22 PM EDTCIK 1070081Accession 0001628280-26-058901
Share

Company context

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.

Current securities

Recent company filings

  1. Regulation FD Disclosure · Other EventsSep 21, 2026
  2. 144 filingSep 9, 2026
  3. Entry into a Material Definitive AgreementAug 28, 2026
  4. 144 filingAug 19, 2026
  5. 144 filingAug 17, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗